Gillian McGovern, Editor

New findings suggest that differences in immune reconstitution kinetics may drive variations in graft-versus-host disease incidence, infection risk, and overall survival.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

Real-world data reveal that moderate to severe depression is linked to poor control and adherence, and women are more likely to be impacted.

The approval is supported by data from the phase 3 TROPION-Breast02 trial.

This FAQ covers current dispensing regulations, practical considerations for pharmacists, and the clinical pharmacology of mifepristone.

GLP-1 receptor agonists may reduce asthma flare-ups in nondiabetic adults with obesity, hinting at anti-inflammatory benefits.

MS care shifts to smoldering progression and biomarkers; learn how pharmacists guide DMT choices, monitoring, and emerging BTK inhibitor therapy.

Ashlan Kunz Coyne, PharmD, MPH, discusses treating Pseudomonas–Stenotrophomonas coinfections, co-culture insights, and smart empiric therapy amid rising resistance.

Three psychiatric pharmacists highlight trends in psychiatric pharmacotherapy that were shared at the AAPP 2026 Annual Meeting.

Pharmacists push antimicrobial stewardship into clinics and long-term care, tackling antifungal resistance, rapid diagnostics, vaccines, and public health leadership.

Kunz Coyne expresses interest in antimicrobial stewardship discussions at the joint MAD-ID/SIDP meeting as clinicians continue refining their role in practice.

Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.

Pharmacists can counter misinformation on SSRIs with evidence-based antidepressant guidance, safe tapering advice, and patient-centered depression care.

Efficacy and safety were evaluated in the phase 3 IMvigor011 trial.

Maroney discussed the pharmacist’s role in patient education, safe medication management, and incorporating broader treatment strategies into individualized mental health care plans.

FDA approves benralizumab for hypereosinophilic syndrome, driven by NATRON phase 3 clinical trial data showing fewer flares and improved fatigue.

The ruling comes after weeks of uncertainty for patients, health care providers, and pharmacists about how and whether they could access and distribute the drug.

FDA approves sonrotoclax for patients who have received at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

The study authors also emphasized that close monitoring during gabapentinoid treatment is necessary, and concomitant use with opioids or benzodiazepines should be avoided.

PMOS to replace PCOS, highlighting metabolic and endocrine roots and a 3-year global rollout aimed at faster diagnosis and better care.

Pharmacists are vital in identifying at-risk patients, supporting diagnostic testing, optimizing therapy, and monitoring medication adjustments.

FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.

In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.

The initiatives have intensified discussion surrounding the use of SSRIs, their discontinuation, and broader approaches to mental health care.

The temporary order will allow patients to continue receiving mifepristone via mail or at the pharmacies without an in-person visit to a doctor.

Ambulatory pharmacists can address mental health gaps, tackle stigma and SDOH, and power collaborative care, improving adherence and patient quality of life.

The approval follows positive results from a phase 3 randomized withdrawal trial.

NABP’s new uniform pharmacy law exam streamlines multistate licensure, reshapes MPJE prep, and speeds pharmacist mobility in 2026.

This new podcast will explore therapies, trends, and clinical decisions shaping neurology from a pharmacist's point of view.

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.